Yingfei Fan "Settled" in Xinhua Pharmacy
Release time:
2020-07-15
The number of designated charity drug donation varieties in Jinqu region has reached 16
. Recently, the first PD-L1 immunotherapy drug duvalizumab (Yingfeifan) approved for listing in China has officially started to be sold. Xinhua Pharmacy, the peak pharmacy, has become the only designated pharmacy in Yingfeifan in Jinqu region and is also the designated service point for charity drug donation in Yingfeifan. On March 27, Xinhua Pharmacy completed the first sale of Yingfeifan, which was delivered to patients by licensed pharmacists in the pharmacy.
Infeifan was formally approved by the National Drug Administration (NMPA) in December 2019 for the treatment of patients with unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after receiving platinum-based chemotherapy and concurrent radiotherapy. The results of phase III PACIFIC clinical trials show that the use of Imfinzi immunotherapy after concurrent radiotherapy and chemotherapy reduces the risk of death by nearly 32% in patients with stage III inoperable NSCLC. The median progression-free survival (PFS) is 16.8 months, and the 3-year overall survival rate (OS) is as high as 57%. Infineon is the first PD-L1 immunosuppressant approved for the treatment of stage III lung cancer in mainland China. The approval marks a new era of immunotherapy for unresectable stage III non-small cell lung cancer in China.
In order to improve the accessibility and standardization of lung cancer immunotherapy for lung cancer patients, reduce the economic burden of patients and prolong the life of patients. The China Primary Health Care Foundation officially launched the "Aifan-Lung Cancer Immunotherapy Patient Assistance Project" on February 29. Patients with low-income insurance who meet the indications for the treatment of duvalizumab can receive free charity drugs until the disease progresses. In the first round, patients can get 2 courses of drug assistance free of charge after using 2 courses of duvalizumab at their own expense; in the second round, patients can get 4 courses of drug assistance free of charge after using 4 courses of duvalizumab at their own expense; in the third round, patients can get 8 courses of free drug assistance after using 6 courses of duvalizumab at their own expense, under the premise that the disease does not progress, the subsequent application for drug donation can be circulated. After investigation and evaluation in various aspects, Xinhua Pharmacy has become a designated service point for charity drug donation in Yingfeifan in Jinliqu area.
Xinhua Pharmacy is a designated pharmacy for serious illness medical insurance in Jinhua City, with complete drug equipment. All hardware facilities are perfect. For drugs that need to be refrigerated, pharmacies have special refrigerators for storage. The refrigerators are equipped with monitoring probes, which are connected to the mobile phone system. If the temperature is abnormal, SMS alarm will be issued. At the same time, Xinhua Pharmacy is also equipped with special personnel to provide drug donation services, which have previously been identified as designated service points for charity drug donation of many varieties such as Terrisa, Iressa, Gnico, Herceptin and Libitai. After Yingfeifan "settled down", there are 16 varieties of designated charity drugs in Jinqu area of Xinhua drugstore. (Reporter Ni Yingzhen)
More information
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-22
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-30
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
Chairman Jiang Xiaomeng Directs Work in Yunnan Peak
On December 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, went to Yunnan Jianfeng cement company to investigate and guide the work. On the morning of the same day, accompanied by the Yunnan peak management team, Jiang Xiaomeng went deep into the front line and successively went to the central control room of the production and manufacturing department, the raw material clay yard, the lignite yard and other areas for field investigation and investigation to understand the problems existing in the production and operation process. Subsequently, a business analysis meeting was held to make a comparative analysis of the various business indicators of Yunnan Jianfeng from January to November this year, and put forward two requirements to the management team: further strengthen internal management and improve execution; strengthen the coordination of external relations, and improve The ability and level of enterprise resource acquisition. At the Yunnan Jianfeng middle-level cadre meeting held on the afternoon of the 16th, Jiang Xiaomeng first fully affirmed Yunnan Jianfeng's highest output and best benefits since it was put into production in 2018, and expressed his gratitude to all cadres and employees of Yunnan Jianfeng for their hard work. After that, Jiang Xiaomeng made a detailed analysis of the cement industry and the regional market environment in Yunnan, and combined with the current production and operation situation of Yunnan Jianfeng, put forward the focus of the next step: 1. should fully attach importance to and mobilize the initiative and responsibility of employees at all levels to improve the overall execution of the team; 2. raw material mines are an important factor restricting the future development of cement enterprises, which should be paid full attention to and formulate clear strategies and methods, set out a timetable to obtain future production resources as much as possible; 3. continuously advocate and promote technological innovation, keep pace with the times, continuously improve production management, equipment management, production technology level, and maintain the competitive advantage of the industry; 4. further strengthen production
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page